These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 25324279

  • 1. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
    Chen Y, Mao J, Hop CE.
    Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
    [Abstract] [Full Text] [Related]

  • 2. P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.
    McDonald MG, Au NT, Rettie AE.
    Drug Metab Dispos; 2015 Nov; 43(11):1661-9. PubMed ID: 26296708
    [Abstract] [Full Text] [Related]

  • 3. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J, Zhou D, Li Y, Khanh BH.
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [Abstract] [Full Text] [Related]

  • 4. A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.
    Lu JT, Cai Y, Chen F, Jia WW, Hu ZY, Zhao YS.
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):689-703. PubMed ID: 26254911
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
    Konishi K, Minematsu T, Nagasaka Y, Tabata K.
    Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
    [Abstract] [Full Text] [Related]

  • 7. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M, Ishizuka T, Inoue SI, Rozehnal V, Fischer T, Sugiyama D.
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [Abstract] [Full Text] [Related]

  • 8. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
    Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD.
    Drug Metab Dispos; 2009 Aug; 37(8):1587-97. PubMed ID: 19420129
    [Abstract] [Full Text] [Related]

  • 9. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M, Inoue SI, Sugiyama D, Nishiya Y, Ishizuka T, Watanabe A, Watanabe K, Yamashita S, Watanabe N.
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [Abstract] [Full Text] [Related]

  • 10. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
    Min JS, Kim D, Park JB, Heo H, Bae SH, Seo JH, Oh E, Bae SK.
    Drug Des Devel Ther; 2016 Apr; 10():2959-2972. PubMed ID: 27695293
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
    Li X, Junge L, Taubert M, von Georg A, Dahlinger D, Starke C, Frechen S, Stelzer C, Kinzig M, Sörgel F, Jaehde U, Töx U, Goeser T, Fuhr U.
    J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L, Liu X.
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
    Yamazaki S, Johnson TR, Smith BJ.
    Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
    [Abstract] [Full Text] [Related]

  • 18. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
    Wang J, Xia S, Xue W, Wang D, Sai Y, Liu L, Liu X.
    Eur J Pharm Sci; 2013 Nov 20; 50(3-4):290-302. PubMed ID: 23916407
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, Jin JY.
    Clin Pharmacokinet; 2016 Nov 20; 55(11):1435-1445. PubMed ID: 27225997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.